Tags

Type your tag names separated by a space and hit enter

[Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)].
Minerva Ginecol. 1996 Jan-Feb; 48(1-2):5-9.MG

Abstract

AIM

To evaluate the use of UGP (urinary gonadotropin protein) as a tumor marker in gynaecologic and obstetric malignant diseases.

MATERIALS AND METHODS

The study was carried out in the division of Gynaecology and Obstetrics of the Ospedali Riuniti in Bergamo. 63 patients, with obstetric or gynaecologic benign or malignant diseases, entered the study. 66 healthy volunteers were examined as a group-control. In both the groups UGP levels were determined in morning urine, using an immunoenzymatic commercial kit.

RESULTS

Results, expressed in fmol UGP/ml of urin, show that UGP is produced by several neoplasms, but the false-positive percentage is still high; a higher precision can be obtained with an accurate choice of the cut-off value and with a standardization of the analytical technics. Besides, the contemporary determination of UGP and CA 125 levels reduces the possibility of false-positive and false-negative results.

CONCLUSIONS

More studies must be carried out to confirm the value of UGP as a tumor marker in obstetrics and gynaecology. Anyway, this recently purified protein can already be useful, in combination with the usual tumor markers, in the prompt diagnosis and management of primary neoplasms or recurrences, with a higher sensibility in comparison with traditional clinical and radiological examinations.

Authors+Show Affiliations

Divisione di Ostetricia e Ginecologia I, Ospedali Riuniti, Bergamo.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

ita

PubMed ID

8750482

Citation

Radici, E, et al. "[Preliminary Experience With a New Tumor Marker in Obstetrics and Gynecology: UGP (Urinary Gonadotropin Protein)]." Minerva Ginecologica, vol. 48, no. 1-2, 1996, pp. 5-9.
Radici E, Persiani P, Stroppa S, et al. [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)]. Minerva Ginecol. 1996;48(1-2):5-9.
Radici, E., Persiani, P., Stroppa, S., Lombardi, P. L., & Torre, G. C. (1996). [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)]. Minerva Ginecologica, 48(1-2), 5-9.
Radici E, et al. [Preliminary Experience With a New Tumor Marker in Obstetrics and Gynecology: UGP (Urinary Gonadotropin Protein)]. Minerva Ginecol. 1996 Jan-Feb;48(1-2):5-9. PubMed PMID: 8750482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)]. AU - Radici,E, AU - Persiani,P, AU - Stroppa,S, AU - Lombardi,P L, AU - Torre,G C, PY - 1996/1/1/pubmed PY - 1996/1/1/medline PY - 1996/1/1/entrez SP - 5 EP - 9 JF - Minerva ginecologica JO - Minerva Ginecol VL - 48 IS - 1-2 N2 - AIM: To evaluate the use of UGP (urinary gonadotropin protein) as a tumor marker in gynaecologic and obstetric malignant diseases. MATERIALS AND METHODS: The study was carried out in the division of Gynaecology and Obstetrics of the Ospedali Riuniti in Bergamo. 63 patients, with obstetric or gynaecologic benign or malignant diseases, entered the study. 66 healthy volunteers were examined as a group-control. In both the groups UGP levels were determined in morning urine, using an immunoenzymatic commercial kit. RESULTS: Results, expressed in fmol UGP/ml of urin, show that UGP is produced by several neoplasms, but the false-positive percentage is still high; a higher precision can be obtained with an accurate choice of the cut-off value and with a standardization of the analytical technics. Besides, the contemporary determination of UGP and CA 125 levels reduces the possibility of false-positive and false-negative results. CONCLUSIONS: More studies must be carried out to confirm the value of UGP as a tumor marker in obstetrics and gynaecology. Anyway, this recently purified protein can already be useful, in combination with the usual tumor markers, in the prompt diagnosis and management of primary neoplasms or recurrences, with a higher sensibility in comparison with traditional clinical and radiological examinations. SN - 0026-4784 UR - https://www.unboundmedicine.com/medline/citation/8750482/[Preliminary_experience_with_a_new_tumor_marker_in_obstetrics_and_gynecology:_UGP__Urinary_Gonadotropin_Protein_]_ L2 - https://medlineplus.gov/healthproblemsinpregnancy.html DB - PRIME DP - Unbound Medicine ER -